One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer

To assess the efficacy and safety of ranitidine bismuth citrate plus clarithromycin given for 1 wk in Brazilian patients with peptic ulcer. One hundred and twenty patients with peptic ulcer were randomized in two treatment groups: (1) 1-wk regimen consisting of ranitidine bismuth citrate 400 mg b.i....

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2005-06, Vol.11 (23), p.3566-3569
Main Authors: Mesquita, Maria Aparecida, Lorena, Sonia Letícia Silva, Almeida, Jazon Romilson Souza, Montes, Ciro Garcia, Guerrazzi, Fábio, Campos, Luciana T, Zeitune, José Murilo Rubiota
Format: Article
Language:English
Subjects:
Adult
Aged
Anti-Bacterial Agents - therapeutic use
Anti-Ulcer Agents - therapeutic use
Bismuth - therapeutic use
Brazil
Brief Reports
Clarithromycin - therapeutic use
Drug Therapy, Combination
Female
Helicobacter Infections - drug therapy
Helicobacter pylori
Humans
Male
Middle Aged
Peptic Ulcer - drug therapy
Peptic Ulcer - microbiology
Ranitidine - analogs & derivatives
Ranitidine - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the efficacy and safety of ranitidine bismuth citrate plus clarithromycin given for 1 wk in Brazilian patients with peptic ulcer. One hundred and twenty patients with peptic ulcer were randomized in two treatment groups: (1) 1-wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d. or (2) 2-wk regimen of the same treatment. Eradication of the infection was considered when both the histologic examination and the urease test were negative for the infection 3 mo after treatment. By intention to treat analysis, Helicobacter pylori (H pylori) was eradicated in 73% and 76% of patients, respectively treated for 1 or 2 wk (P>0.05). By per protocol analysis, the eradication rates were 80% and 83%, respectively, in patients treated for 1 or 2 wk (P>0.05). Nine patients (8.2%) reported minor side effects. One-week therapy with ranitidine bismuth citrate and clarithromycin is safe, well tolerated and effective for treatment of H pylori infection, and appears to be comparable to the 2-wk regimen in terms of efficacy.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v11.i23.3566